EP3981420A1 — Method of treating patients with hepatorenal syndrome type 1

USPTO Abstract

The principles and embodiments of the present disclosure relate to methods for using terlipressin to treat a patient HRS-1 in a patient who does not have overt sepsis, septic shock, or uncontrolled infection despite antibiotic treatment and meeting at least two of the following criteria: (i) a white blood cell count either less than 4,000 cells/mm<sup>3</sup> or greater than 12,000 cells/mm<sup>3</sup>, (ii) a heart rate of greater than 90 beats per minute, and(iii) either HCO<sub>3</sub><23 mmol/L or PaCO<sub>2</sub><32 mmHg or >20 breaths per minute; wherein said treatment results in a reduction in patient serum creatinine level, and comprises measuring a baseline serum creatinine level in the blood of the patient prior to treatment or on day 1 of treatment with terlipressin;treating the patient with terlipressin;measuring the patient's serum creatinine level after treatment has begun; and observing the serum creatinine level in the blood of the patient decreased upon treatment with terlipressin.